CCL2 and colonic neoplasm: Losartan and its primary metabolite, EXP-3174, inhibit CCL2-mediated monocyte recruitment to the metastatic site through the inhibition of CCL2-induced Erk1/2 activation and significantly reduce the metastatic burden in breast and colon cancer models [105].